Aditya Birla Sun Life Quant Fund
Direct · GrowthAI Summary
Aditya Birla Sun Life Quant Fund delivered a 1Y SIP XIRR of 8.44%, which trails the category average SIP XIRR of 10.69% by about 2.25 percentage points. Against the NIFTY 50, the fund shows positive alpha across all periods, with 1Y alpha of 9.52% and a Fund CAGR of -1.99% versus the benchmark's -11.43%, indicating meaningful downside protection. However, the long-term lump-sum CAGRs remain slightly negative, suggesting weak absolute compounding over extended windows.
The fund's maximum drawdown of just -0.23% with only one drawdown event above 10% reflects exceptionally low realized volatility, though the 524-day recovery period indicates slow rebound from troughs. A Calmar ratio of 0.253 over 1Y suggests modest risk-adjusted returns relative to the drawdown experienced. Downside capture of 89.18% versus upside capture of 101.96% over 1Y confirms the fund captures more upside than downside, a favorable asymmetry.
The portfolio holds 44 stocks with a well-diversified top 10, where the largest position, Federal Bank, is only 4.68% of NAV. Sector exposure is led by Banks at 15.3% and Pharmaceuticals & Biotechnology at 13.2%, with cement, industrial products, and finance providing further spread. No single sector exceeds 16%, indicating the quant model maintains broad diversification rather than concentrated thematic bets.
Despite its Sectoral/Thematic classification, the fund behaves like a diversified large-cap strategy with beta near 1.00, which may explain its underperformance versus thematic peers whose category average SIP XIRR ranges from 10.69% (1Y) to 17.47% (5Y). Its consistent positive alpha over the benchmark across 1Y to 15Y windows shows steady relative discipline. Calendar year returns of -5.48% (2026), 7.46% (2025), and -4.00% (2024) reveal choppy absolute performance in recent years.
This fund suits conservative investors seeking index-like market exposure with quant-driven downside mitigation rather than aggressive thematic returns. A horizon of at least 5-7 years is appropriate given the extended drawdown recovery periods and muted long-term CAGRs. Investors should have moderate risk tolerance and should not expect the high-octane returns typical of the Sectoral/Thematic category.
- Consistent positive alpha versus NIFTY 50 across all measured periods, with 1Y alpha of 9.52%
- Favorable capture asymmetry: 101.96% upside capture versus 89.18% downside capture over 1Y
- Highly diversified 44-stock portfolio with no single holding above 4.68% of NAV and a reasonable 0.72% expense ratio for the Direct plan
- 1Y SIP XIRR of 8.44% underperforms the category average of 10.69%, and long-term lump-sum CAGRs remain negative
- Slow recovery from drawdowns (524 days) and a modest Calmar ratio of 0.253 indicate weak risk-adjusted compounding despite low volatility
Generated on 21-10-2026, 3:09 AM. Verify before investing.
Gives more importance to longer time periods (10Y, 20Y) than shorter ones (1Y, 3Y). This balances out recent outperformance and gives a more realistic picture of what long-term returns might look like.
The largest peak-to-trough decline in the fund's NAV. Shows the worst-case loss an investor would have experienced at any point in the fund's history.
If you invested ₹1,00,000 every month via SIP, here's how this fund has historically performed across different time horizons.
| Duration | Invested | Median Value | XIRR | Min XIRR | Max XIRR |
|---|---|---|---|---|---|
| 1 Year | ₹12.00 L | ₹12.41 L | 8.1% | -14.4% | 24.6% |
SIP returns vs benchmark & category
Annualised SIP return (XIRR) over each rolling horizon — like-for-like, not lump-sum.
| Duration | Fund SIP XIRR | NIFTY 50 | Category avg | Fund edge |
|---|---|---|---|---|
| 1 Year | 8.1% | 14.3% | 10.6% | -6.2% |
| Duration | Mean | Median | Min | Max | Sharpe | Sortino | % Positive | Cat. Mean | Cat. Median |
|---|---|---|---|---|---|---|---|---|---|
| 1 Year | 5.7% | 6.9% | -11.2% | 26.1% | -0.10 | -0.13 | 74% | — | — |
Calmar Ratio by Duration
Compared against NIFTY 50
| Duration | Alpha | Beta | Upside Capture | Downside Capture | Fund CAGR | Bench CAGR |
|---|---|---|---|---|---|---|
| 1 Year | +8.14 | 1.01 | 101.7% | 91.8% | -4.7% | -12.7% |
| 3 Years | +0.48 | 1.00 | 98.9% | 97.7% | -1.7% | -2.1% |
| 5 Years | +0.30 | 1.00 | 98.9% | 97.7% | -1.0% | -1.3% |
| 7 Years | +0.22 | 1.00 | 98.9% | 97.7% | -0.7% | -0.9% |
| 10 Years | +0.16 | 1.00 | 98.9% | 97.7% | -0.5% | -0.7% |
| 12 Years | +0.13 | 1.00 | 98.9% | 97.7% | -0.4% | -0.5% |
| 15 Years | +0.11 | 1.00 | 98.9% | 97.7% | -0.3% | -0.4% |
| # | Stock | % of NAV |
|---|---|---|
| 1 | The Federal Bank Limited | 4.68% |
| 2 | Marico Limited | 3.83% |
| 3 | State Bank of India | 3.77% |
| 4 | Apollo Hospitals Enterprise Limited | 3.75% |
| 5 | Ashok Leyland Limited | 3.74% |
| 6 | Grasim Industries Limited | 3.67% |
| 7 | Sun Pharmaceutical Industries Limited | 3.34% |
| 8 | Torrent Pharmaceuticals Limited | 3.32% |
| 9 | Bharti Airtel Limited | 3.27% |
| 10 | Laurus Labs Limited | 3.16% |